Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.
Barclays raises its price target on NorthWestern Energy Group (NWE) to $62, citing solid quarterly performance and strategic moves, including a pending merger with Black Hills Corporation, as the regulated utility reaffirms its long-term growth outlook.
UBS analyst Peter Grom increased his price target for Kimberly-Clark (KMB) to $110, citing steady core performance despite lingering Kenvue-related uncertainties, after the consumer goods giant reported better-than-expected quarterly profit driven by cost discipline and resilient demand.
TD Cowen raises Prudential Financial's price target to $113, maintaining a 'Hold' rating, as the insurer grapples with a misconduct scandal at its Japan life insurance unit affecting nearly 500 customers.
Scotiabank has lowered its price target for Comcast (CMCSA), reflecting ongoing pressure in its core broadband business as the media giant reports higher-than-expected customer losses in Q4 and faces fierce competition from fiber and fixed-wireless rivals.
Amid a choppy market landscape in early 2026, value investors are scanning for opportunities. We analyze three companies—Viavi Solutions, Kontoor Brands, and Robert Half—whose current share prices appear significantly disconnected from their estimated intrinsic worth based on cash flow projections.
Amid a resilient but mixed market, companies with significant insider ownership are drawing investor attention. We examine three firms—spanning crypto, consumer staples, and finance—where management's substantial equity stakes align with ambitious earnings growth forecasts of up to 124%.
A landmark investment proposal between AI titans Nvidia and OpenAI has stalled, with both companies reassessing terms amid internal concerns and a shifting competitive landscape, according to a Wall Street Journal report.
The all-stock deal creates a top-tier independent producer focused on the Permian Basin, with Beth McDonald at the helm aiming to unlock significant synergies and shareholder returns.
Precious metals extended their sharp decline following President Trump's nomination for the next Federal Reserve chair, a move markets interpret as locking in higher interest rates and boosting the U.S. dollar's appeal.
Private equity firm Exponent has halted the auction of UK accounting group Xeinadin after potential buyers refused to meet its £1bn valuation, signaling potential headwinds for deal-making in the professional services sector.
Millions rely on Medicare, yet common misunderstandings about its coverage rules and costs can lead to significant financial shocks in retirement. We clarify three critical areas where assumptions often prove wrong.
Afya Ltd., a leading medical education group in Brazil, is demonstrating robust financial health with a rising Return on Capital Employed (ROCE) and significant capital expansion. While its stock has faced headwinds, the underlying operational metrics suggest a company efficiently reinvesting for growth, presenting a potential opportunity for value-focused investors.
A wave of insider buying at 908 Devices Inc. has caught the market's attention, signaling potential optimism among those who know the company best. While not a guaranteed predictor, such coordinated activity often precedes significant corporate developments.
While Vidhance (FRA:8W50) continues to operate at a loss, its current cash reserves and manageable burn rate suggest the company has time to execute its growth strategy. However, a recent dip in revenue adds a note of caution for investors.
Iranian authorities announced the arrest of four foreigners allegedly involved in last month's widespread unrest, seizing homemade explosives in the operation as the government continues to blame external actors for domestic turmoil.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
A deep dive into the conflicting signals from Church & Dwight's stock valuation. While a discounted cash flow model suggests a significant discount, its premium P/E ratio tells a different story, leaving investors to weigh pricing power against market expectations.
A deep dive into Truist Financial's valuation suggests its current share price may not fully reflect its underlying earnings power and book value, presenting a potential opportunity for investors.
A recent revision to RenaissanceRe Holdings' official price target has refocused market attention on the reinsurer, highlighting how evolving analyst assumptions—rather than a specific number—are reshaping the investment narrative around the stock.
